Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
After finishing at $8.76 in the prior trading day, Avid Bioservices Inc (NASDAQ: CDMO) closed at $8.38, down -4.34%. In other words, the price has decreased by -$4.34 from its previous closing price. On the day, 1.01 million shares were traded. CDMO stock price reached its highest trading level at $8.8 during the session, while it also had its lowest trading level at $8.3.
Ratios:
Our goal is to gain a better understanding of CDMO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.31 and its Current Ratio is at 0.46. In the meantime, Its Debt-to-Equity ratio is 1.09 whereas as Long-Term Debt/Eq ratio is at 0.29.
On March 14, 2023, KeyBanc Capital Markets Upgraded its rating to Overweight which previously was Sector Weight but kept the price unchanged to $20.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 30 ’24 when Green Nicholas Stewart sold 11,762 shares for $7.40 per share. The transaction valued at 87,028 led to the insider holds 203,606 shares of the business.
Hart Daniel R sold 2,826 shares of CDMO for $20,910 on Apr 30 ’24. The Chief Financial Officer now owns 82,221 shares after completing the transaction at $7.40 per share. On Apr 30 ’24, another insider, Ziebell Mark R, who serves as the V. P., General Counsel of the company, sold 1,643 shares for $7.40 each. As a result, the insider received 12,157 and left with 64,834 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CDMO now has a Market Capitalization of 531960736 and an Enterprise Value of 721700992. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.89 while its Price-to-Book (P/B) ratio in mrq is 2.95. Its current Enterprise Value per Revenue stands at 5.278 whereas that against EBITDA is -114.229.
Stock Price History:
The Beta on a monthly basis for CDMO is 1.52, which has changed by -0.5125209 over the last 52 weeks, in comparison to a change of 0.2537824 over the same period for the S&P500. Over the past 52 weeks, CDMO has reached a high of $18.65, while it has fallen to a 52-week low of $4.07. The 50-Day Moving Average of the stock is 18.32%, while the 200-Day Moving Average is calculated to be 5.74%.
Shares Statistics:
The stock has traded on average 1.40M shares per day over the past 3-months and 1391940 shares per day over the last 10 days, according to various share statistics. A total of 63.48M shares are outstanding, with a floating share count of 62.80M. Insiders hold about 1.08% of the company’s shares, while institutions hold 99.32% stake in the company. Shares short for CDMO as of 1713139200 were 10322378 with a Short Ratio of 7.36, compared to 1710460800 on 10842004. Therefore, it implies a Short% of Shares Outstanding of 10322378 and a Short% of Float of 19.399999.
Earnings Estimates
The dynamic stock of Avid Bioservices Inc (CDMO) is currently attracting attention from 4.0 analysts actively involved in rating its market status.On average, analysts expect EPS of -$0.04 for the current quarter, with a high estimate of -$0.03 and a low estimate of -$0.05, while EPS last year was $0. The consensus estimate for the next quarter is -$0.05, with high estimates of -$0.05 and low estimates of -$0.05.
Analysts are recommending an EPS of between -$0.31 and -$0.33 for the fiscal current year, implying an average EPS of -$0.32. EPS for the following year is -$0.19, with 4.0 analysts recommending between -$0.16 and -$0.22.
Revenue Estimates
5 analysts predict $42.14M in revenue for the current quarter. It ranges from a high estimate of $42.93M to a low estimate of $41M. As of the current estimate, Avid Bioservices Inc’s year-ago sales were $39.8MFor the next quarter, 5 analysts are estimating revenue of $40.72M. There is a high estimate of $41.86M for the next quarter, whereas the lowest estimate is $39.5M.
A total of 5 analysts have provided revenue estimates for CDMO’s current fiscal year. The highest revenue estimate was $139.87M, while the lowest revenue estimate was $137.9M, resulting in an average revenue estimate of $139.08M. In the same quarter a year ago, actual revenue was $149.27MBased on 5 analysts’ estimates, the company’s revenue will be $164M in the next fiscal year. The high estimate is $175M and the low estimate is $153.2M.
